Journey Medical Corporation (DERM Quick QuoteDERM - Free Report) reported $18.97 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 7.6%. EPS of -$0.05 for the same period compares to -$0.09 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $20.54 million, representing a surprise of -7.66%. The company delivered an EPS surprise of -66.67%, with the consensus EPS estimate being -$0.03.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Journey Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total net product revenue- Accutane: $3.02 million versus the two-analyst average estimate of $3.19 million. The reported number represents a year-over-year change of +9.2%.
• Total net product revenue- EmrosiTM: $9 million compared to the $10.31 million average estimate based on two analysts. The reported number represents a change of +84.4% year over year.
• Total net product revenue- Qbrexza: $5.59 million versus the two-analyst average estimate of $5.71 million. The reported number represents a year-over-year change of -24.1%.

View all Key Company Metrics for Journey Medical here>>>

Shares of Journey Medical have returned -15.9% over the past month versus the Zacks S&P 500 composite's -2.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.